Isorhamnetin
Research reviewed: Up until 03/2026
Isorhamnetin (Isorhamnetin (3'-methoxy-3,4',5,7-tetrahydroxyflavone)) is a dietary supplement with 8 published peer-reviewed studies involving 2,493 participants, researched for Cancer Prevention & Anti-tumour Activity, Cardiovascular & Metabolic Effects, Anti-inflammatory & Skin Protection and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Cancer Prevention & Anti-tumour Activity
WeakCardiovascular & Metabolic Effects
ModerateAnti-inflammatory & Skin Protection
WeakSystematic Evidence
WeakResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Cancer Prevention & Anti-tumour Activity
To investigate isorhamnetin's anti-proliferative effects in lung cancer cells.
Study Type
In vitro study
Purpose
To investigate isorhamnetin's anti-proliferative effects in lung cancer cells.
Dose
10-100 µM isorhamnetin
Participants
A549 and H460 non-small cell lung cancer cells
Duration
48 hours
Results
Isorhamnetin significantly inhibited lung cancer cell proliferation; induced G2/M arrest and caspase-3-mediated apoptosis; PI3K/Akt and ERK pathways suppressed.
How They Measured It
MTT assay, flow cytometry cell cycle analysis, caspase-3 activation
To evaluate isorhamnetin chemoprevention of skin carcinogenesis induced by DMBA/TPA in mice.
Study Type
Animal study
Purpose
To evaluate isorhamnetin chemoprevention of skin carcinogenesis induced by DMBA/TPA in mice.
Dose
1% isorhamnetin topical application
Participants
DMBA/TPA two-stage skin carcinogenesis model
Duration
20 weeks
Results
Isorhamnetin significantly inhibited tumour multiplicity (-65%) and incidence; suppressed NF-kB activation and inflammatory mediators in skin tissue.
How They Measured It
Skin tumour incidence and multiplicity; oxidative stress markers; NF-kB activation
To assess isorhamnetin's ability to induce differentiation and apoptosis in colorectal cancer cells.
Study Type
In vitro study
Purpose
To assess isorhamnetin's ability to induce differentiation and apoptosis in colorectal cancer cells.
Dose
25-100 µM isorhamnetin
Participants
SW480 and HCT116 colorectal cancer cell lines
Duration
72 hours
Results
Isorhamnetin induced cancer cell differentiation and apoptosis via Wnt/beta-catenin pathway inhibition; PCNA expression markedly reduced.
How They Measured It
Alkaline phosphatase (differentiation marker), PCNA, Wnt/beta-catenin signalling
Cardiovascular & Metabolic Effects
To assess dietary isorhamnetin intake (from sea buckthorn and other sources) and cardiovascular risk markers.
Study Type
Observational cohort
Purpose
To assess dietary isorhamnetin intake (from sea buckthorn and other sources) and cardiovascular risk markers.
Dose
Dietary intake (observational)
Participants
1200 adults in Nordic prospective study
Duration
5 years
Results
Higher isorhamnetin intake associated with lower triglycerides and LDL-C; inverse association with hypertension prevalence.
How They Measured It
Serum lipids, blood pressure, inflammatory markers; FFQ dietary assessment
To investigate isorhamnetin's cardioprotective mechanisms in doxorubicin-induced cardiomyopathy.
Study Type
Animal study
Purpose
To investigate isorhamnetin's cardioprotective mechanisms in doxorubicin-induced cardiomyopathy.
Dose
25-75 mg/kg isorhamnetin
Participants
Rat doxorubicin cardiotoxicity model
Duration
2 weeks
Results
Isorhamnetin significantly protected cardiac function, reduced troponin I release, and preserved mitochondrial integrity via AMPK activation.
How They Measured It
Cardiac troponin I, LDH, ROS, mitochondrial integrity, AMPK activation
Anti-inflammatory & Skin Protection
To evaluate isorhamnetin's anti-inflammatory activity in LPS-stimulated macrophages.
Study Type
In vitro study
Purpose
To evaluate isorhamnetin's anti-inflammatory activity in LPS-stimulated macrophages.
Dose
5-40 µM isorhamnetin
Participants
RAW264.7 macrophages
Duration
12-24 hours
Results
Isorhamnetin potently inhibited NO production, iNOS expression, and NF-kB activation; reduced TNF-alpha and IL-6 by >50% vs LPS alone.
How They Measured It
NO production, iNOS expression, NF-kB nuclear translocation, cytokine secretion
To assess isorhamnetin's photoprotective effects against UV-induced damage in keratinocytes.
Study Type
In vitro skin study
Purpose
To assess isorhamnetin's photoprotective effects against UV-induced damage in keratinocytes.
Dose
5-20 µM isorhamnetin pre-treatment
Participants
Human HaCaT keratinocytes
Duration
UV irradiation + 24-hour
Results
Isorhamnetin significantly reduced UV-induced ROS, CPD formation, and p53-dependent apoptosis; mechanism included UV absorption and direct radical quenching.
How They Measured It
Cell viability post-UV, ROS levels, CPD formation, p53 activation
Systematic Evidence
To review isorhamnetin's pharmacological properties, bioavailability, and therapeutic prospects.
Study Type
Systematic review
Purpose
To review isorhamnetin's pharmacological properties, bioavailability, and therapeutic prospects.
Dose
Varied
Participants
Multiple studies reviewed
Duration
Review
Results
Isorhamnetin is a quercetin metabolite with potent anti-cancer, anti-inflammatory, and cardioprotective activities; sea buckthorn berries represent the richest food source; pharmacokinetics warrant further human study.
How They Measured It
Systematic literature synthesis
Frequently Asked Questions
Common questions about Isorhamnetin research
There are currently 8 peer-reviewed studies on Isorhamnetin (Isorhamnetin (3'-methoxy-3,4',5,7-tetrahydroxyflavone)), involving 2,493 total participants. Research covers Cancer prevention, Cardiovascular health, Anti-inflammatory and 1 more areas. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (1 human study), and reported outcomes.
Isorhamnetin has been researched for: Cancer prevention, Cardiovascular health, Anti-inflammatory, Skin protection. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 1 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
